|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Cutsem E, Peeters M, Siena S, Humblet
Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J,
Richardson G, et al: Open-label phase III trial of panitumumab plus
best supportive care compared with best supportive care alone in
patients with chemotherapy-refractory metastatic colorectal cancer.
J Clin Oncol. 25:1658–1664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adachi T, Hinoi T, Egi H, Shimomura M and
Ohdan H: Oxaliplatin and molecular-targeted drug therapies improved
the overall survival in colorectal cancer patients with synchronous
peritoneal carcinomatosis undergoing incomplete cytoreductive
surgery. Surg Today. 45:986–992. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beppu N, Yoshie H, Kimura F, Aihara T, Doi
H, Kamikonya N, Matsubara N, Tomita N, Yanagi H and Yamanaka N: The
short-term outcomes of induction SOX (S-1 + oxaliplatin) +/−
cetuximab chemotherapy followed by short-course chemoradiotherapy
in patients with poor-risk locally advanced rectal cancer. Surg
Today. 46:1123–1131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keyse SM: Dual-specificity MAP kinase
phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27:253–261.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dunn KL, Espino PS, Drobic B, He S and
Davie JR: The Ras-MAPK signal transduction pathway, cancer and
chromatin remodeling. Biochem Cell Biol. 83:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoon S and Seger R: The extracellular
signal-regulated kinase: Multiple substrates regulate diverse
cellular functions. Growth Factors. 24:21–44. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leslie H, Sobin MKG and Christian
Wittekind: TNM classification of malignant tumors. 7th.
Wiley-Blackwell; 2011
|
|
15
|
Larionov A, Krause A and Miller W: A
standard curve based method for relative real time PCR data
processing. BMC Bioinformatics. 6:622005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yao R, Maeda T, Takada S and Noda T:
Identification of a PDZ domain containing Golgi protein, GOPC, as
an interaction partner of frizzled. Biochem Biophys Res Commun.
286:771–778. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neudauer CL, Joberty G and Macara IG:
PIST: A novel PDZ/coiled-coil domain binding partner for the
rho-family GTPase TC10. Biochem Biophys Res Commun. 280:541–547.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pelaseyed T and Hansson GC: CFTR anion
channel modulates expression of human transmembrane mucin MUC3
through the PDZ protein GOPC. J Cell Sci. 124:3074–3083. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Charest A, Lane K, McMahon K and Housman
DE: Association of a novel PDZ domain-containing peripheral Golgi
protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive
fusion protein (NSF) attachment protein receptor) protein syntaxin
6. J Biol Chem. 276:29456–29465. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meiffren G, Joubert PE, Gregoire IP,
Codogno P, Rabourdin-Combe C and Faure M: Pathogen recognition by
the cell surface receptor CD46 induces autophagy. Autophagy.
6:299–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu R, Stewart L and Wilson JM: Scaffolding
protein GOPC regulates tight junction structure. Cell Tissue Res.
360:321–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Charest A, Lane K, McMahon K, Park J,
Preisinger E, Conroy H and Housman D: Fusion of FIG to the receptor
tyrosine kinase ROS in a glioblastoma with an interstitial
del(6)(q21q21). Genes Chromosomes Cancer. 37:58–71. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saborowski A, Saborowski M, Davare MA,
Druker BJ, Klimstra DS and Lowe SW: Mouse model of intrahepatic
cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene
and therapeutic target. Proc Natl Acad Sci USA. 110:19513–19518.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deng G, Hu C, Zhu L, Huang F, Huang W, Xu
H and Nie W: Downregulation of ROS-FIG inhibits cell proliferation,
colony formation, cell cycle progression, migration and invasion,
while inducing apoptosis in intrahepatic cholangiocarcinoma cells.
Int J Mol Med. 34:661–668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng J, Cebotaru V, Cebotaru L and
Guggino WB: Syntaxin 6 and CAL mediate the degradation of the
cystic fibrosis transmembrane conductance regulator. Mol Biol Cell.
21:1178–1187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng J, Moyer BD, Milewski M, Loffing J,
Ikeda M, Mickle JE, Cutting GR, Li M, Stanton BA and Guggino WB: A
Golgi-associated PDZ domain protein modulates cystic fibrosis
transmembrane regulator plasma membrane expression. J Biol Chem.
277:3520–3529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng J, Wang H and Guggino WB: Regulation
of cystic fibrosis transmembrane regulator trafficking and protein
expression by a Rho family small GTPase TC10. J Biol Chem.
280:3731–3739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao TT, Deacon HW, Reczek D, Bretscher A
and von Zastrow M: A kinase-regulated PDZ-domain interaction
controls endocytic sorting of the beta2-adrenergic receptor.
Nature. 401:286–290. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
He J, Bellini M, Xu J, Castleberry AM and
Hall RA: Interaction with cystic fibrosis transmembrane conductance
regulator-associated ligand (CAL) inhibits beta1-adrenergic
receptor surface expression. J Biol Chem. 279:50190–50196. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bauch C, Koliwer J, Buck F, Hönck HH and
Kreienkamp HJ: Subcellular sorting of the G-protein coupled mouse
somatostatin receptor 5 by a network of PDZ-domain containing
proteins. PLoS One. 9:e885292014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng S, Zhang J, Zhu P, Ma Y, Xiong Y,
Sun L, Xu J, Zhang H and He J: The PDZ domain protein CAL interacts
with mGluR5a and modulates receptor expression. J Neurochem.
112:588–598. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang J, Cheng S, Xiong Y, Ma Y, Luo D,
Jeromin A, Zhang H and He J: A novel association of mGluR1a with
the PDZ scaffold protein CAL modulates receptor activity. FEBS
Lett. 582:4117–4124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wente W, Stroh T, Beaudet A, Richter D and
Kreienkamp HJ: Interactions with PDZ domain proteins PIST/GOPC and
PDZK1 regulate intracellular sorting of the somatostatin receptor
subtype 5. J Biol Chem. 280:32419–32425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koliwer J, Park M, Bauch C, von Zastrow M
and Kreienkamp HJ: The golgi-associated PDZ domain protein
PIST/GOPC stabilizes the β1-adrenergic receptor in intracellular
compartments after internalization. J Biol Chem. 290:6120–6129.
2015. View Article : Google Scholar : PubMed/NCBI
|
